CervoMed (CRVO) said it has completed enrollment in its Phase 2a study of Neflamapimod for Nonfluent Var—an important trial-milestone moving the program forward. No efficacy or safety results were disclosed in the update, so near-term implications appear incremental but supportive for ongoing clinical progress.
CervoMed (CRVO) said it has completed enrollment in its Phase 2a study of Neflamapimod for Nonfluent Var—an important trial-milestone moving the program forward. No efficacy or safety results were disclosed in the update, so near-term implications appear incremental but supportive for ongoing clinical progress.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.22
Ticker Sentiment
